Page 13 Medical & Healthcare Expert Guide 2019
P. 13
13
www.sintetica.com
Sintetica S.A. - Elisabetta Donati
Via Penate 5, 6850 Mendrisio, Switzerland
Established 1921 in Switzerland, Sintetica possess sites which are
based in Switzerland, Germany, Austria, Italy and United Kingdom,
with its headquarters in Mendrisio, Switzerland. With 300 people
employed around Europe, the workforce is diverse, coming from 29
different countries across the globe. Sintetica’s primary focus is on
local anaesthesia and pain relief.
As of 2012, Sintetica established its global division, which was
the first international corporate structure. The global division was
tasked with pursuing international growth under two distinct
models, being a B2B licensing strategy and somewhat later a B2C
strategy in selected markets. Elisabetta outlines Sintetica’s overall
mission, discussing what steps are taken in order to achieve the
leadership, and how employees integrate innovation into every
aspect of its work.
Here at Sintetica, we are fully committed
to innovating therapies and drugs in
local anaesthesia, pain management and
neuromodulation. As such, we move forward
with passion and competence in the full respect
of people and the environment. All our efforts
and resources are focused on becoming a leader
in these fields, by developing novel medicine
and better treatment options for physicians and
patients worldwide.
Sintetica recently gained approval in the US for a New Drug
Application – Clorotekal (spinal Chloroprocaine mainly conceived
for the fast track anaesthesia in day surgery cases, enhancing the
recovery after surgery). Elisabetta added: “This is an outstanding
achievement. In fact, we are one of the few small medium-sized
companies in the world which actually managed to register an
original innovative medicine in the United States”. Sintetica
managed all trials from cell and animal toxicity, to clinical research
on human beings, obviously going through pharmaceutical
development.
Moreover the firm has submitted over 400 product registrations in
over 100 different countries world-wide, via the network of partners
it has built. The impressive technological enhancement of the
last decade has strongly changed many surgical procedures and
perioperative practices. Novel therapies and treatments require
more and more the redevelopment of existing drugs. “As such,
we enhance drug formulation, assuring the fitting of our ‘Premix’
medicines to the current standard of care” Clara Bianchi, Pharma
R&D manager reflects.
Surgical procedures become less and less invasive and their
duration reduces, while there is an increased cost pressure on the
health system which is leading to a shift towards day surgery.
“Modern short and medium acting local anaesthetics are our ‘One
Day Surgery’ proposal, enabling physicians to adapt the length and
the conditions of anaesthesia to the novel surgical needs, allowing
patients to go home on the same day” concludes Barbara Piccagli,
Clinical R&D manager.
www.sintetica.com
Sintetica S.A. - Elisabetta Donati
Via Penate 5, 6850 Mendrisio, Switzerland
Established 1921 in Switzerland, Sintetica possess sites which are
based in Switzerland, Germany, Austria, Italy and United Kingdom,
with its headquarters in Mendrisio, Switzerland. With 300 people
employed around Europe, the workforce is diverse, coming from 29
different countries across the globe. Sintetica’s primary focus is on
local anaesthesia and pain relief.
As of 2012, Sintetica established its global division, which was
the first international corporate structure. The global division was
tasked with pursuing international growth under two distinct
models, being a B2B licensing strategy and somewhat later a B2C
strategy in selected markets. Elisabetta outlines Sintetica’s overall
mission, discussing what steps are taken in order to achieve the
leadership, and how employees integrate innovation into every
aspect of its work.
Here at Sintetica, we are fully committed
to innovating therapies and drugs in
local anaesthesia, pain management and
neuromodulation. As such, we move forward
with passion and competence in the full respect
of people and the environment. All our efforts
and resources are focused on becoming a leader
in these fields, by developing novel medicine
and better treatment options for physicians and
patients worldwide.
Sintetica recently gained approval in the US for a New Drug
Application – Clorotekal (spinal Chloroprocaine mainly conceived
for the fast track anaesthesia in day surgery cases, enhancing the
recovery after surgery). Elisabetta added: “This is an outstanding
achievement. In fact, we are one of the few small medium-sized
companies in the world which actually managed to register an
original innovative medicine in the United States”. Sintetica
managed all trials from cell and animal toxicity, to clinical research
on human beings, obviously going through pharmaceutical
development.
Moreover the firm has submitted over 400 product registrations in
over 100 different countries world-wide, via the network of partners
it has built. The impressive technological enhancement of the
last decade has strongly changed many surgical procedures and
perioperative practices. Novel therapies and treatments require
more and more the redevelopment of existing drugs. “As such,
we enhance drug formulation, assuring the fitting of our ‘Premix’
medicines to the current standard of care” Clara Bianchi, Pharma
R&D manager reflects.
Surgical procedures become less and less invasive and their
duration reduces, while there is an increased cost pressure on the
health system which is leading to a shift towards day surgery.
“Modern short and medium acting local anaesthetics are our ‘One
Day Surgery’ proposal, enabling physicians to adapt the length and
the conditions of anaesthesia to the novel surgical needs, allowing
patients to go home on the same day” concludes Barbara Piccagli,
Clinical R&D manager.
